Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBUS study of nebulised liposomal amphotericin B lung deposition in chronic pulmonary aspergillosis
NL-OMON60453Phase 1Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amphotericin b in chronic pulmonary aspergillosis (CPA), sponsored by Radboud University Medical Center. Primary endpoints: Pulmonary deposition of AmBisome, Pulmonary deposition versus blood concentrations and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
amphotericin b
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on NL-OMON60453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60453.